The initial muscle loss seen with GLP-1 RA treatment as well as the ongoing replacement of muscle with fat with treatment cycles involving treatment interruptions can result in unfavorable changes in body composition in patients with obesity that can have profoundly negative repercussions, and can exacerbate obesity-related metabolic and health concerns 14,15,16
But heres what didnt happen: no changes in libido, morning vigor, or any other metric of male performance
Causes & What to Know Many patients taking GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), or liraglutide (Victoza, Saxenda) report changes in urination patterns
10.1093/bja/85.1.136 6
Microporous Mesoporous Mater
Metabolic Research and Tissue Maintenance The physiological observations associated with this blend often center on body composition and tissue health models